A New Immunotherapy Method in Cancer Treatment: The Anti-GARP Antibody

According to a study published in Nature Communications on September 11, 2020, scientists successfully neutralized a molecule that prevents the immune system from acting against cancer, called GARP. The research team also discovered that this method enhanced the effect of another well-known immunotherapy that is not always effective in every cancer type, and enabled the tumor to regress.
Cancer immunotherapy is a treatment method that triggers the body’s naturally occurring immune responses to attack tumor cells. These responses are often suppressed by various cells or molecules, making it easier for tumor cells to escape the immune system and grow. This is one of the most frequently encountered situations in cancer treatment and adversely affects treatment response.
In 2004, Prof. Sophie Lucas began to study the tumor microenvironment by investigating the function of the immunosuppressive cells frequently observed there. The aim of the study was to identify and eliminate suppressive cells, thereby enabling antibodies to act against tumor cells. The experiments identified the cell group found at high concentrations in patients with cancer that causes suppression of the immune system: regulatory T lymphocytes (Treg).
Continuing her work on this subject, Prof. Lucas succeeded in identifying the function of a molecule displayed on the surface of regulatory T lymphocytes in 2018. GARP is the name of this molecule, which acts as a messenger for regulatory T lymphocytes, sending immune-suppressing signals. The team then developed an antibody that binds to GARP and prevents it from sending signals: the anti-GARP antibody.
The team’s first test results were published in August 2020. According to the results of this highly exciting study, in experiments using animal models, anti-GARP antibodies inhibited the activity of regulatory T lymphocytes. This creates an immune response against tumor cells and destroys them. The effectiveness of the anti-GARP antibody was also investigated in combination with anti-PD1 antibodies, which have proven effectiveness and are used in certain cancer types. Combining immunotherapy methods that trigger immune system activity through two different mechanisms increased the effectiveness of cancer treatment.
This new method, which is at the preclinical research stage, is extremely important for the future. Conducting the same tests in humans may provide a more effective treatment in the fight against cancer.
Sources
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
Nature Communications, 11 Sep 2020.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.